SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, or MSK for short, and AstraZeneca have joined forces to address global inequalities in comprehensive cancer care. The collaboration between the biotech company, cancer treatment center and pharmaceutical company aims to improve access to advanced cancer testing and data on a global scale. With cancer being the second leading cause of death worldwide, this partnership seeks to tackle the lack of adequate testing, particularly in low- and middle-income countries.
The partnership will allow the three entities to create a decentralized global network for cancer testing. Through the SOPHiA DDM platform, MSK’s proprietary cancer tests will be made available to organizations with support from AstraZeneca’s global footprint. This technology-agnostic platform will enable institutions, including those in underserved regions, to make data-driven decisions and enhance cancer diagnosis and treatment.
The program is expected to be available for healthcare institutions before the end of 2023. This collaboration aims to generate a comprehensive dataset sourced from diverse populations, providing insights that could shape the future of global healthcare.
